%0 Journal Article
%T High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer
%A Yang, Xueli
%A Zhang, Zhengquan
%A Jia, Xiaoqing
%A Zhang, Yanqin
%A Mu, Tianyang
%A Zhou, Bingzheng
%A Li, Lin
%A Fu, Deyuan
%A Hu, Xin
%A Xiong, Shunbin
%J Journal of Thoracic Disease
%D 2017
%B 2017
%9 
%! High expression of PLA2G16 is associated with a better prognosis in HER2-positive breast cancer
%K 
%X Background: PLA2G16 functions as a phosphatase in metabolism and its abnormal expression is closely associated with tumor progression. The aim of this study is to investigate the prognosis value of PLA2G16 in breast cancer.   Methods: A tissue microarray including 200 invasive ductal carcinoma specimens was constructed. Immunohistochemistry was performed to determine the PLA2G16 expression status. The Kaplan-Meier analysis and log-rank test were used to evaluate the prognostic value of PLA2G16. The Multivariate Cox regression analysis was performed to identify whether PLA2G16 was an independent prognostic factor.  Results: In our retrospective study, Kaplan-Meier analysis showed that elevated PLA2G16 expression was correlated with improved DFS (P=0.032) in the whole breast cancer patients. In further subgroup analysis, PLA2G16 overexpression was found to be associated with prolonged DFS (P=0.018) in HER2-positive breast cancer patients. More importantly, Multivariate analysis suggested that PLA2G16 was a significant independent prognostic factor in HER2-enriched patients [hazard ratio (HR) =0.151; 95% confidence interval (CI) =0.034–0.672; P=0.013].   Conclusions: Our study evaluated the prognostic significance of PLA2G16 in patients with HER2-positive breast cancer and confirmed the relevance of this metabolism-related gene in patient outcome.
%U https://jtd.amegroups.org/article/view/12624
%V 9
%N 4
%P 1002-1011
%@ 2077-6624